Representatives of Moderna Biotech UK and NHS England will also be questioned by the inquiry, led by crossbench peer Baroness ...

Moderna Inc. said Thursday a Phase 3 trial of its next-generation COVID-19 vaccine met its main goal and showed higher efficacy in adults age 18 and older compared with its original vaccine ...

Moderna’s combined coronavirus-influenza shot produced a higher immune response in older adults than separate vaccines for those viruses administered together, according to data the company ...

Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $1.5 billion to $2.5 billion -- down from ...

As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural ...

The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal ...

Investors should be aware of 2025 headwinds, including declining COVID-19 vaccine sales and potential regulatory impacts from RFK Jr.'s appointment. During the pandemic, Moderna took advantage of ...

The early stage company is developing a new approach to gene editing to treat rare genetic diseases. It does this using mRNA, ...

A guide to the coronavirus vaccination rollout and what you need to know about the authorized vaccines Some 63.8% of Americans have received both doses of the two-shot Pfizer-BioNTech and Moderna ...